Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stock Watch: After The Pandemic, Different Vaccines To The Rescue

Pfizer’s Third-Quarter Results Included Belated Acceptances And Echoes For GSK

Executive Summary

From the unfavorable comparisons brought about by lower pandemic-related product sales, vaccines for other diseases bring hopes for longer-term success.

You may also be interested in...

Stock Watch: Where Novo And Lilly Lead, Others Follow

AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.

Abrysvo Launch A Bright Spot For Pfizer In A Third Quarter Reset

The RSV vaccine performed well in the third quarter but is in a competitive fight with GSK’s Arexvy. Pfizer also announced Phase III results for its mRNA-based flu vaccine.

Stock Watch: Immunity Debt And Vaccine Investment

A rise in childhood pneumonia in China and The Netherlands raised fears of another pandemic but the variety of identified pathogens gave way to the concept of ‘immunity debt’ resulting from the last pandemic.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts